| Literature DB >> 35808086 |
Ramin Boroujerdi1, Richard Paul1.
Abstract
Sensors developed from nanomaterials are increasingly used in a variety of fields, from simple wearable or medical sensors to be used at home to monitor health, to more complicated sensors being used by border customs or aviation industries. In recent times, nanoparticle-based sensors have begun to revolutionize drug-detection techniques, mainly due to their affordability, ease of use and portability, compared to conventional chromatography techniques. Thin graphene layers provide a significantly high surface to weight ratio compared to other nanomaterials, a characteristic that has led to the design of more sensitive and reliable sensors. The exceptional properties of graphene coupled with its potential to be tuned to target specific molecules have made graphene-based sensors one of the most popular and well-researched sensing materials of the past two decades with applications in environmental monitoring, medical diagnostics, and industries. Here, we present a review of developments in the applications of graphene-based sensors in sensing drugs such as cocaine, morphine, methamphetamine, ketamine, tramadol and so forth in the past decade. We compare graphene sensors with other sensors developed from ultrathin two-dimensional materials, such as transition-metal dichalcogenides, hexagonal boron nitrate, and MXenes, to measure drugs directly and indirectly, in various samples.Entities:
Keywords: 2D materials; electrochemical sensors; forensic science; graphene; pharmaceutical biosensors; toxicology
Year: 2022 PMID: 35808086 PMCID: PMC9267978 DOI: 10.3390/nano12132250
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.719
Figure 1Molecular structure of the depressant and stimulant drugs studied in this review.
Figure 2(A) DP voltammograms for morphine at the Zn2SnO4-GO/CPE in the presence of 10 μmol L-1 codeine in buffer solution (pH = 7.0); pulse amplitude = 50 mV and pulse time = 50 ms. (B) DP voltammograms for codeine at the Zn2SnO4-GO/CPE in the presence of 10 μmol L-1 morphine. (C) DP voltammograms for different concentrations of morphine and codeine in pH 7.0 B-R buffer solution. Adapted with permission from ref. [38]. Copyright 2016 RSC.
Figure 3Schematic representation of the fabrication of the working paper-based electrode and the sensing mechanism of ketamine. Adapted with permission from ref. [75]. Copyright 2017 ELSEVIER.
Figure 4(A,B), at the top, show an overview of the setup and all connections and the schematic of the setup with all essential components marked. 1: stage; 2: holder; 3: fabricated graphene-based device; 4: PDMS-based flow chamber; 5: PMMA lid; 6: needle pin probes; 7: microfluidic tubing. General scheme for the detection of different analytes with the fabricated graphene-based device including additional exposure to light to investigate the discovered photo-physical response illustrated in the box at the bottom (C). Adapted with permission from ref. [85]. Copyright 2019 MDPI.
Figure 5Schematic representation of the laser-induced porous graphene electrode fabrication and the components of the developed portable methamphetamine sensor illustrated at the top of the figure. (A,B) show the analytical characteristics of the sensor: (A) DPV responses of MA in the developed portable device. (B) DPV responses of MA, while showing inset—amplified anodic peak current of MA at a concentration of 1.00 µg mL−1. Adapted with permission from ref. [93]. Copyright 2022 MDPI.
Figure 6The SEM images of the surface of bare GCE (A), ErGO/GCE (B), and Fe3O4@PPy/ErGO/GCE (C). The Nyquist plots (D) and CVs (E) (recorded at scan rate of 50 mV/s) of bare GC (curve a), ErGO/GC (curve b) and Fe3O4@PPy/ErGO/GC (curve c) in solution containing KCl (0.1 M) and Fe(CN)63-/4- (5 mM). EIS conditions: initial potential, 0.17 V; frequency range, 100 kHz to 0.1 Hz. Adapted with permission from ref. [94]. Copyright 2021 ELSEVIER.
Comparison of functionalizations, method of measurement and LoD of graphene-based electrochemical sensors for the determination of drugs in various samples.
| NO | Drug(s) Detected | Sensing Material | Main Method(s) | Detection Limit(s) | Sample(s) | Ref. |
|---|---|---|---|---|---|---|
|
| Morphine | Graphene oxide–Co3O4 | DPV/CV | 0.54 nM | Urine, Medical tablets | [ |
|
| Morphine | Graphene–Pd NPs | DPV | 12.95 nM | Urine | [ |
|
| Morphine | Graphene–Cu-poly(Ala) | DPV | 47 nM | Blood serum | [ |
|
| Morphine | Graphene-MWCNTs | CV | 50 nM | Urine | [ |
|
| Morphine | Graphene oxide–poly(CTAB) | DPV/CV | 360 nM | Blood serum, Urine | [ |
|
| Morphine | Graphene oxide–Fe3O4@SiO2 | DPV/CV | 750 nM | Urine, Medical ampoule | [ |
|
| Morphine | Graphene–Au NPs-MO antibody | SWV | 90 pg/mL | Saliva | [ |
|
| Morphine | N-S-doped graphene | CV | 0.26 μg/mL | Soft drinks, Beer, Vodka | [ |
|
| Heroin, Morphine, Noscapine | Graphene | DPV | 500, 400 and 200 nM | None | [ |
|
| Morphine and Codeine | Graphene–Zn2SO4 | DPV/CV | 11 and 9 nM | Urine, Plasma, Medical tablets | [ |
|
| Codeine | 3D spongy graphene–adenine | SWV | 5.8 nM | Plasma, Solpadeine tablets | [ |
|
| Codeine | Graphene–Nafion | SWV | 15 nM | Urine, Cough syrup | [ |
|
| Codeine and Acetaminophen | Graphene–CoFe2O4 | SWV | 25 and 11 nM | Plasma, Urine, Medical tablets, Expectorant Cod syrup | [ |
|
| pholcodine | Graphene–(PHL)2+-(NB)− | POT | 0.04 μg/mL | Medical suspensions, Medical syrups | [ |
|
| Ketamine | Graphene oxide–Zeo | CV | 0.001 nM | Whisky, Juice | [ |
|
| Ketamine and Norketamine | Graphene–MOF-MIM | DPV | 0.04 nM | Urine, Saliva | [ |
|
| Tramadol | Graphene–Ag NPs-MIP | CV | 2.04 nM | Urine, Medical tablets | [ |
|
| Tramadol | 1-M-3-BBr-Pr(OH)3-GQD | CV | 3 nM | Medical injection, Blood serum | [ |
|
| Tramadol | Graphene oxide–MWCNTs | CV | 15 nM | Plasma, Medical tablets | [ |
|
| Tramadol | Graphene–Co3O4 | LSV/DPV | 30 nM | Urine, Medical tablets | [ |
|
| Tramadol and Acetaminophen | Graphene–NiFe2O4 | SWV | 3.6 and 3 nM | Blood serum, Urine, Medical tablets, Ultracet tablet | [ |
|
| Tramadol and Acetaminophen | Graphene–Au NPs-HTP | DPV | 820 nM | Urine, Medical tablets | [ |
|
| Methadone | Graphene–Ag NPs | DPV | 120 nM | Blood serum | [ |
|
| Methadone and Morphine | Graphene–TGA@CdSe | DPV | 40 nM and 30 nM | Blood serum | [ |
|
| Buprenorphine | Graphene | DPV/CV | 160 nM | Urine | [ |
|
| Cocaine | 3D printed Graphene–PLA | SWV/CV | 6 μM | None | [ |
|
| Cocaine | Graphene–Pd NPs-MIP | SWV | 50 μM | Saliva, River water, street sample | [ |
|
| Cocaine and Amphetamine | Graphene–(pyrene-NHS)-antibody | TLM | NA | None | [ |
|
| Methamphetamine | Graphene–Fe3O4@PPy | CV/SWV | 1 nM | Blood serum, Urine | [ |
|
| Methamphetamine | Graphene–Ce2O3 | SWV | 8.75 μM | Plasma | [ |
|
| Methamphetamine | 3D Porous Graphene | DPV/CV | 0.31 μg/mL | Saliva, Household surfaces | [ |
Atlas of 2D materials based on metals and transition metals.
| Class of 2D Material | Mono-Layer Molecular Structure | Possible “M/M’”s | Possible “X/Y”s |
|---|---|---|---|
| Semimetal Chalcogenides (MCs) | M’X | Ga and In | S, Se and Te |
| Transition Metal Chalcogenides (TMCs) | MX | Transition metals between group 4 and group 10 | |
| M3X4 | |||
| Transition Metal Dichalcogenides (TMDs) | MX2 | ||
| Transition Metal Halides (TMHs) | MY2 | Cl, Br and I | |
| MY3 | |||
| Transition Metal Carbides, Nitrides and Carbonitrides (MXenes) | M2X | C and N | |
| M3X2 | |||
| M4X3 |
Comparison of the LoD of ultrathin material-based sensors and biosensors.
| Analyte | 2D Base Material | Sensing Materials | Limit of Detection | Ref. |
|---|---|---|---|---|
| Dopamine | Graphene | G-C3N4/CuO | 0.1 nM | [ |
| rGO-poly(Cu-AMT) | 3.48 nM | [ | ||
| PEDOT/GO/in vivo carbon fiber | 85 nM | [ | ||
| TMDs | MoSe2/Graphene | 1 nM | [ | |
| MoS2 | 1 µM | [ | ||
| MXenes | Ti3C2Tx/Pt-NPs | 6 nM | [ | |
| Ti3C2Tx | 100 nM | [ | ||
| MIP/G-QDs/h-BN | 20 pM | [ | ||
| BP | BP | NA | [ |
Comparison of electrochemical sensors and chromatography techniques.
| Analyte | Experimental Technique | Duration of Analysis a | Detection Limit | Ref. |
|---|---|---|---|---|
| Morphine | HPLC-UV | 10 min | 1 ng/mL | [ |
| GC-MS | 11 min | 3 ng/mL | [ | |
| CV | 24 s b | 0.54 nM | [ | |
| Tramadol | HPLC-UV | 40 min | 6.7 ng/mL | [ |
| GC-MS | 9 min | 0.77 ng/mL | [ | |
| CV | 3.4 s b | 2.04 nM | [ | |
| Cocaine | HPLC-Fluorescence | 8 min | 1 ng/mL | [ |
| GC-MS | 16 min | 0.05 ng/mL | [ | |
| CV | 60 s b | 6 μM | [ | |
| Methamphetamine | HPLC-MS | 12 min | 0.05 ng/mL | [ |
| GC-MS | 18 min | 0.06 μg/mL | [ | |
| CV | 40 s b | 1 nM | [ |
a: Run time—the pretreatment process time of samples excluded. b: Full CV cycle at studied scan rate—in case of single potential measurements, it will take less than 1 s.